TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of TRACON Pharmaceuticals stock opened at $0.03 on Thursday. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75. The firm has a market capitalization of $100,536.00, a P/E ratio of 0.01 and a beta of 1.43. The business has a fifty day simple moving average of $0.08 and a two-hundred day simple moving average of $0.56.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.